Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

Similar presentations


Presentation on theme: "Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)"— Presentation transcript:

1 Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment by Volker Kunzmann, Thomas Ruediger, Michael Hallek, Hans-Konrad Mueller-Hermelink, and Martin Wilhelm Blood Volume 98(6): September 15, 2001 ©2001 by American Society of Hematology

2 Tumor cell agglutination within blood vessels
Tumor cell agglutination within blood vessels.Original magnification was × 100. Tumor cell agglutination within blood vessels.Original magnification was × 100. (A) Brain (H&E stain) agglutination of large lymphoid blasts with abundant mitoses within small capillaries. Marked perivascular edema. (B) Brain (immunhistology) CD20 expression of the tumor cells within the blood vessels proving them to be of B lineage. Volker Kunzmann et al. Blood 2001;98: ©2001 by American Society of Hematology


Download ppt "Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)"

Similar presentations


Ads by Google